ES2060603T3 - El uso de la proteina vp6 nucleocapsida de rotavirus en composiciones de vacunas. - Google Patents

El uso de la proteina vp6 nucleocapsida de rotavirus en composiciones de vacunas.

Info

Publication number
ES2060603T3
ES2060603T3 ES87307746T ES87307746T ES2060603T3 ES 2060603 T3 ES2060603 T3 ES 2060603T3 ES 87307746 T ES87307746 T ES 87307746T ES 87307746 T ES87307746 T ES 87307746T ES 2060603 T3 ES2060603 T3 ES 2060603T3
Authority
ES
Spain
Prior art keywords
rotavirus
vaccine compositions
carrier
nucleocapside
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES87307746T
Other languages
English (en)
Inventor
Marta Iris Sabara
Patrick John Frenchick
Kerry Frances Mullin-Ready
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Saskatchewan
Original Assignee
University of Saskatchewan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Saskatchewan filed Critical University of Saskatchewan
Application granted granted Critical
Publication of ES2060603T3 publication Critical patent/ES2060603T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12311—Rotavirus, e.g. rotavirus A
    • C12N2720/12322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

LOS NUEVOS SOPORTES INMUNOLOGICOS COMPLEJOS SON SUMINISTRADOS UTILIZANDO EL POLIPEPTIDO VP6 DE ROTAVIRUS COMO LA MOLECULA DE SOPORTE. TAMBIEN SE PROPORCIONAN METODOS PARA LIGAR MOLECULAS PORTADORAS EPITOPE, (COMO HAPTENOS), A LA MOLECULA PORTADORA VP6 A TRAVES DE PEPTIDOS LIGADOS. EL SOPORTE VP6 PUEDE SER UN MONOMERO VP6, UN OLIGOMERO, O UNA PARTICULA QUE TIENE OLIGOMEROS VP6.
ES87307746T 1986-09-03 1987-09-02 El uso de la proteina vp6 nucleocapsida de rotavirus en composiciones de vacunas. Expired - Lifetime ES2060603T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US90322286A 1986-09-03 1986-09-03

Publications (1)

Publication Number Publication Date
ES2060603T3 true ES2060603T3 (es) 1994-12-01

Family

ID=25417135

Family Applications (1)

Application Number Title Priority Date Filing Date
ES87307746T Expired - Lifetime ES2060603T3 (es) 1986-09-03 1987-09-02 El uso de la proteina vp6 nucleocapsida de rotavirus en composiciones de vacunas.

Country Status (10)

Country Link
EP (1) EP0259149B1 (es)
JP (1) JPS63218627A (es)
AT (1) ATE98493T1 (es)
AU (1) AU608769B2 (es)
CA (1) CA1319101C (es)
DE (1) DE3788475T2 (es)
DK (1) DK171602B1 (es)
ES (1) ES2060603T3 (es)
IE (1) IE61417B1 (es)
IL (1) IL83755A (es)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6086880A (en) * 1985-12-26 2000-07-11 The University Of Saskatchewan Rotavirus peptide compositions and methods of use
CA1340530C (en) * 1989-04-28 1999-05-04 Kok Kheong Lee Synthetic pseudomonas aeruginosa pilin peptide and related vaccines and diagnostics
GB9000143D0 (en) * 1990-01-04 1990-03-07 Natural Environment Res Test kit and method for the diagnosis of bluetongue
US5298244A (en) * 1990-10-25 1994-03-29 University Of Saskatchewan Assembled viral particles and their use in a vaccine to rotaviral disease
US5431899A (en) * 1991-02-04 1995-07-11 University Of Saskatchewan Rotavirus VP6 as a diagnostic and targeting agent
AU660168B2 (en) * 1991-02-04 1995-06-15 University Of Saskatchewan VP6 encapsulated drug delivery
DE69433160T2 (de) 1993-05-12 2004-07-08 Chiron Corp. (N.D.Ges.D. Staates Delaware), Emeryville Konserviertes Motiv der Hepatitis C Virus E2/NS1 Region
US5820868A (en) 1993-12-09 1998-10-13 Veterinary Infectious Disease Organization Recombinant protein production in bovine adenovirus expression vector system
US6150137A (en) 1994-05-27 2000-11-21 Ariad Pharmaceuticals, Inc. Immunosuppressant target proteins
US6777217B1 (en) 1996-03-26 2004-08-17 President And Fellows Of Harvard College Histone deacetylases, and uses related thereto
DE19618797C2 (de) * 1996-05-10 2000-03-23 Bertling Wolf Vehikel zum Transport molekularer Substanz
WO1998050071A1 (en) * 1997-05-01 1998-11-12 Chiron Corporation Use of virus-like particles as adjuvants
JP4812914B2 (ja) 1997-06-23 2011-11-09 ユニバーシティ オブ サスカチュワン ウシアデノウイルスタイプ３ゲノム
DE19750354A1 (de) * 1997-11-13 1999-05-27 November Ag Molekulare Medizin Verfahren zur Applikation von Wirkstoffen
US6492343B1 (en) 1998-04-15 2002-12-10 University Of Saskatchewan Porcine adenovirus type 3 genome
DE19829005C2 (de) * 1998-06-29 2000-08-31 November Ag Molekulare Medizin Verfahren zum Transport molekularer Substanz in vorgegebene Bereiche eukaryontischer Zellen
WO2000026395A2 (en) 1998-11-02 2000-05-11 University Of Saskatchewan Bovine cells expressing adenovirus essential functions for propagation of recombinant adenoviral vectors
PL192016B1 (pl) 1998-11-30 2006-08-31 Cytos Biotechnology Ag Kompozycja, sposób wytwarzania sztucznego, uporządkowanego i powtarzalnego układu antygenu, zastosowanie kompozycji oraz kompozycja szczepionki
US6299882B1 (en) 1999-04-09 2001-10-09 Schering Corporation UL54.5 of Marek's disease virus (MDV)
US6451319B1 (en) 1999-04-09 2002-09-17 Schering-Plough Veterinary Corporation Recombinant and mutant adenoviruses
DE19916224C1 (de) 1999-04-10 2000-06-21 November Ag Molekulare Medizin Synthetisches biologisch aktives Molekül
US7396905B1 (en) 1999-05-21 2008-07-08 Mckeon Frank Calcipressins: endogenous inhibitors of calcineurin, uses and reagents related thereto
AU784861B2 (en) 1999-10-21 2006-07-06 Case Western Reserve University Gene expression profiling of inflammatory bowel disease
US20030129724A1 (en) 2000-03-03 2003-07-10 Grozinger Christina M. Class II human histone deacetylases, and uses related thereto
WO2001085208A2 (en) 2000-05-05 2001-11-15 Cytos Biotechnology Ag Molecular antigen arrays and vaccines
CA2410665C (en) 2000-05-31 2017-11-07 University Of Saskatchewan Modified bovine adenovirus having altered tropism
US7320793B2 (en) 2001-01-19 2008-01-22 Cytos Biotechnology Ag Molecular antigen array
US7128911B2 (en) 2001-01-19 2006-10-31 Cytos Biotechnology Ag Antigen arrays for treatment of bone disease
US7094409B2 (en) 2001-01-19 2006-08-22 Cytos Biotechnology Ag Antigen arrays for treatment of allergic eosinophilic diseases
US7244853B2 (en) 2001-05-09 2007-07-17 President And Fellows Of Harvard College Dioxanes and uses thereof
US7569217B2 (en) 2001-09-24 2009-08-04 University Of Saskatchewan Porcine adenovirus E1 and E4 regions
US7115266B2 (en) 2001-10-05 2006-10-03 Cytos Biotechnology Ag Angiotensin peptide-carrier conjugates and uses thereof
JP4726483B2 (ja) 2002-07-17 2011-07-20 サイトス バイオテクノロジー アーゲー 分子抗原アレイ
KR101228376B1 (ko) 2002-07-18 2013-01-31 사이토스 바이오테크놀로지 아게 합텐-캐리어 컨쥬게이트 및 그의 용도
AU2003255967A1 (en) 2002-07-19 2004-02-09 University Of Saskatchewan Pav regions for encapsidation and e1 transcriptioonal control
DE60336902D1 (de) 2002-07-19 2011-06-09 Cytos Biotechnology Ag Impfstoffzusammensetzungen enthaltende amyloid beta 1-6 antigenarrays
US7264818B2 (en) 2003-06-10 2007-09-04 University Of Saskatchewan BAV packaging regions and E1 transcriptional control regions
WO2006021893A2 (en) 2004-08-26 2006-03-02 The University Of Western Ontario Pharmaceutical compositions comprising inhibitors of iron transport, and method of identifying iron transport inhibitors, fn staphylococcus aureus
US8999289B2 (en) 2005-03-22 2015-04-07 President And Fellows Of Harvard College Treatment of protein degradation disorders
EP2224008A3 (en) 2005-05-12 2010-12-01 Murdoch University Genes and proteins of brachyspira hyodysenteriae and use of same for diagnosis and therapy
WO2007059166A2 (en) 2005-11-14 2007-05-24 Weber Georg F Peptide sequence that promotes tumor invasion
US8222423B2 (en) 2006-02-14 2012-07-17 Dana-Farber Cancer Institute, Inc. Bifunctional histone deacetylase inhibitors
AU2007248656B2 (en) 2006-05-03 2013-04-04 Dana-Farber Cancer Institute, Inc. Histone deacetylase and tubulin deacetylase inhibitors
EP2185578A2 (en) 2007-08-03 2010-05-19 Spirogene Pty Ltd Genes and proteins of brachyspira hyodysenteriae and uses thereof
GB0720250D0 (en) 2007-10-17 2007-11-28 Univ Edinburgh Immunogenic compositions containing escherichia coli h7 flagella and methods of use thereof
EP2363407A1 (en) 2008-02-28 2011-09-07 Murdoch University Novel sequences of Brachyspira, immunogenic compositions, methods for preparation and use thereof
US8460681B2 (en) 2008-03-27 2013-06-11 Prionics Ag Sequences of Brachyspira, immunogenic compounds, methods for preparation and use thereof
US8440716B2 (en) 2008-07-23 2013-05-14 President And Fellows Of Harvard College Deacetylase inhibitors and uses thereof
US8716344B2 (en) 2009-08-11 2014-05-06 President And Fellows Of Harvard College Class- and isoform-specific HDAC inhibitors and uses thereof
CN111569056B (zh) * 2020-05-26 2022-09-27 山东信得科技股份有限公司 一种猪轮状病毒疫苗、制备该疫苗的抗原及其编码序列

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3685651T2 (de) * 1985-12-26 1993-01-21 Univ Saskatchewan Den antigenischen und immunogenischen determinanten von wichtigen neutralisierenden proteinen des rotavirus entsprechende peptide.
US5186933A (en) * 1986-12-30 1993-02-16 Baylor College Of Medicine Synthesis and immunogenicity of rotavirus genes using a baculovirus expression system

Also Published As

Publication number Publication date
DE3788475D1 (de) 1994-01-27
CA1319101C (en) 1993-06-15
AU608769B2 (en) 1991-04-18
AU7791887A (en) 1988-03-10
DK460387A (da) 1988-03-04
ATE98493T1 (de) 1994-01-15
DK460387D0 (da) 1987-09-03
EP0259149B1 (en) 1993-12-15
DK171602B1 (da) 1997-02-17
EP0259149A2 (en) 1988-03-09
DE3788475T2 (de) 1994-04-07
EP0259149A3 (en) 1989-05-24
IL83755A (en) 1993-04-04
IE61417B1 (en) 1994-11-02
JPS63218627A (ja) 1988-09-12
IE872353L (en) 1988-03-03
IL83755A0 (en) 1988-02-29

Similar Documents

Publication Publication Date Title
EP0259149A3 (en) The use of rotavirus nucleocapsid protein vp6 in vaccine compositions
FI874287A7 (fi) Uudet lymfokiinipeptidit.
FI943591A7 (fi) Synteettinen hemofilus-influenssa yhdistelmärokote
DK564989A (da) Bindingsproteiner
FI873185L (fi) Nya peptider.
UA27763C2 (uk) Рекомбінантна молекула днк, що кодує молекулу адгезії icam-3, молекула адгезії icam-3, антитіло, здатне зв'язуватись з такою молекулою, фармацевтична композиція
DK0644202T3 (da) Syntetiske antigener til påvisning af antistoffer imod hepatitis C virus
EA200100395A1 (ru) Фармацевтическая композиция, содержащая фрагменты днк, кодирующей антигенный белок, обладающая противоопухолевым действием
ATE133993T1 (de) Protein-antikrebsmittel
SE8604991D0 (sv) Snake venom growth arresting peptide
DK0463053T3 (da) Fremstilling og anvendelse af anthelmintiske midler og beskyttende immunogener
DE3485219D1 (de) Tgf-polypeptide, davon derivierte antigene oligopeptide, davon erhaltene antikoerper.
FI943218A7 (fi) Kaseinomakropeptidin peptidit, mainittujen peptidien vasta-aineet ja k äytöt
NO894573L (no) Rekombinante interleukin-2 hybridproteiner.
DK0474789T3 (da) Peptid med thiol-beskyttet cystein til anvendelse i immnoassays
SE9402253D0 (sv) Process
IT1126709B (it) Procedimento di candeggio ottico per substrati costituiti,in parte o in totalita',da poliammidi sintetiche
FI971086A7 (fi) Kinaasia sitova proteiini ja sen käyttö
ATE130311T1 (de) Mehrfache festphasensynthese von peptiden.
ATE81591T1 (de) Interleukin-2 induziertes antineoplastisches peptid.
DE3873353D1 (de) Reinigung von monomerem interferon.
AU525042B2 (en) Ovulation enhancing peptides
DE69012328D1 (de) Srif-verwandte peptide und deren verwendungen.
PT84798B (de) Cyclische peptide mit cytoprotektiver wirkung
DK369888A (da) Peptidforbindelser

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 259149

Country of ref document: ES